Childhood cancer research gets $30 million from feds

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 9
Volume 17
Issue 9

President George W. Bush approved a bill that devotes $30 million annually over 5 years to fund pediatric cancer research.

President George W. Bush approved a bill that devotes $30 million annually over 5 years to fund pediatric cancer research. The Caroline Pryce Walker Conquer Childhood Cancer Act was introduced by Sen. Jack Reed (D-RI) and Sen. Norm Coleman (R-MN) and was passed unanimously in the summer by the House of Representatives and the U.S. Senate. The legislation was named in memory of Caroline Pryce Walker, daughter of Congresswoman Deborah Pryce (R-OH), who died of neuroblastoma in 1999 at age 9.

 


The new law will support funding for collaborative pediatric cancer clinical trials research and to create a population-based national childhood cancer database. Public education campaigns will also be launched to raise awareness about ongoing research in pediatric cancer, according to the CureSearch National Childhood Cancer Foundation. It has yet to be determined which government agency will administer the grant money, a CureSearch spokesperson told ONI.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content